“So I feel good about that part of our med tech portfolio and be able to sustain that double digit growth going forward.”

In context

“avern, Ambulet three our next generation AMBLET, and, you know, our our mitral replacement valve. I think that's those are all, you know, I actually been pretty close. I've been closer to the mitral replacement program recently. And the feedback that I've heard from this product is just spectacular. And I think it's got the potential to live up to the expectation that we all had back in 2015 when all of us made significant investments in buying early assets and with the belief that my could be as big as TAVR. I think that this is the product that's going to it's got the potential to fulfill that promise. So I put all that together. I think that we're tremendously, competitive position in Structural Heart. Portfolio is very and we're gonna continue to invest in it and and be a leader here. So I feel good about that part of our med tech portfolio and be able to sustain that double digit growth going forward. So well, I I I realize we've we've hit our time here. Let me just make some closing remarks. Delivered another very good quarter. Year to date, we've delivered 7.5% organic growth, 10% EPS. Showing that we can expand our op margin profile. We've expanded that by a 100 basis points. And I think we've delivered all of that as I said, in in in in one of the questions here with some some larger than expected headwinds here that we faced in our businesses that we feel will be kind of behind us, next year. So our organic r and d engine continues to be highly, highly productive. And I expect that we'll be able to sustain this performance, this growth as we as we carry into 2026 and beyond. So with that, I'll wrap it up. And thank you for joining us today. Philip Boudreau: Thank you, operator, an”